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 Multidrug-resistant tuberculosis (MDR TB) is a signiﬁ cant 
threat to global health estimated to account for nearly half a 
million new cases and over 200,000 deaths in 2013. The num-
ber of MDR TB cases in the UK has risen over the last 15 years, 
with ever more complex clinical cases and associated challeng-
ing public health and societal implications. In this review, we 
provide an overview of the epidemiology of MDR TB globally 
and in the UK, outline the clinical management of MDR TB 
and summarise recent advances in diagnostics and prospects 
for new treatment. 
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 Introduction 
 The significant threat of the global multidrug-resistant 
tuberculosis (MDR TB) epidemic has been described as a 
crisis in the World Health Organization's (WHO's)  End TB 
strategy . 1 MDR TB is defined as tuberculosis (TB) caused by 
 Mycobacterium tuberculosis isolates that are resistant to at least 
both rifampicin and isoniazid. 2 The WHO's  Global tuberculosis 
report supplement in 2014 estimated that MDR TB accounts 
for 3.5% (95% confidence interval (CI) 2.2–4.7%) of all new 
cases of TB and 20.5% (95% CI 13.6–27.5%) of TB cases among 
individuals previously treated for the disease. 3 There were 
approximately 480,000 new cases of MDR TB globally in 2013, 
with an estimated 210,000 deaths attributable to MDR TB. The 
highest levels of MDR TB are in Eastern European and Asian 
countries, with more than half the global burden of MDR TB 
being located in India, China and Russia. 4 Additional cause for 
concern is the emergence of extensively drug-resistant TB (XDR 
TB), which is defined as tuberculosis caused by  M tuberculosis 
isolates that are resistant to rifampicin, isoniazid, any 
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fluoroquinolones and at least one of the second-line injectable 
drugs (capreomycin, kanamycin and amikacin). 2 
 Here we provide an overview of the importance of MDR TB, its 
epidemiology, clinical implications, potential ways of addressing 
the disease and prospects for new diagnostics and treatment. 
 Epidemiology 
 Global epidemiology of TB 
 Unfortunately, data on drug resistance are limited by a number 
of factors, including lack of facilities for testing and the 
limited availability of routine surveillance that only occurs in 
approximately 50% of countries. Of the 144 countries known 
to be collecting data on TB drug resistance, 72 have continuous 
surveillance systems in place that are based on drug susceptibility 
testing (DST) of all TB patients. The other 72 countries 
undertake special surveys of representative patient samples every 
3–5 years, with this approach being commonest in settings where 
resources are limited. Out of the 36 high TB and high MDR TB 
countries, 10 have the former surveillance approach, while 26 
have adopted the latter. Molecular technologies are increasingly 
being used for surveillance: examples include GenoType® 
MTBDRplus (Hain Lifescience, Nehren, Germany) and Xpert® 
MTB/RIF (Cepheid Inc, Sunnyvale, CA, USA). 
 Among newly diagnosed cases of TB, the highest levels 
of MDR TB have been found in Belarus (35.2% in 2013), 
Kyrgyzstan (26.4% in 2011) and Kazakhstan (25.2% in 2013). 
Among previously treated cases, the levels are highest in the 
Republic of Moldova (62.3% in 2012), Uzbekistan (62.0% in 
2011) and Tajikistan (56.0% in 2012). 
 The total number of formally notified cases globally was 
136,412 cases of MDR TB or rifampicin-resistant TB (RR TB) 
in 2013, substantially lower than the estimated 300,000 (range 
230,000–380,000) MDR TB cases among pulmonary TB cases 
and 480,000 (range 350,000–610,000) incident MDR TB cases 
among all cases. The majority of these reported cases arose 
from Europe (45,136), India (35,385) and South Africa (26,023). 
The higher number of MDR TB cases in 2013 compared to 
2012 was due to the increase in the number of cases in India 
(increased from 21,498 to 35,385), Uzbekistan (increased from 
2,233 to 5,751) and Ukraine (increased from 7,615 to 10,585). 
Between 2012 and 2013, MDR TB and RR TB notifications 
increased in the Democratic Republic of Congo, Myanmar, 
Tajikistan and Uzbekistan while notifications decreased in 
Belarus, Bulgaria, Estonia, Kazakhstan, Kyrgyzstan, Latvia, 
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Lithuania and the Russian Federation. China reported 4,183 
cases of MDR TB/RR TB of its estimated 54,000 MDR TB cases 
in 2013. In the same year, the Russian Federation reported 33% 
of its estimated number of MDR TB cases. 
 Globally, 48% of MDR TB patients from 2011 successfully 
completed treatment while 25% were either lost to follow-up 
or had no information available about their final outcome. The 
highest success rates were in the Eastern Mediterranean (64%), 
while the lowest were in the European and African regions 
(less than 50%). The highest treatment failure rate was in the 
European region (15%) while the highest death rate was in 
South-East Asia (21%). 4  
 Epidemiology of TB in the UK 
 In 2013, there were 7,892 cases of TB notified in the UK with an 
incidence of 12.3/100,000. 5 The majority of these cases (73%) 
occurred in non-UK born individuals. Generally, however, the 
number of TB cases has fallen by 11.6% over the preceding two 
years owing to a small decrease in the number and rate of cases 
among the non-UK born population. TB continues to remain 
a health problem linked to socioeconomic status: 70% of TB 
cases lived in the 40% most deprived areas in the country; 
almost half of the cases were unemployed. Geographically, the 
greatest number of cases occurred in London, which accounted 
for 37.8% (2,985/7,892) of all TB cases with an incidence of 
35.5/100,000 (95% CI 34.2–36.8). The most common countries 
of origin for non-UK born TB cases out of the 5,415 cases with 
a known foreign place of birth were India (1,615), Pakistan 
(1,103) and Somalia (292). 
 There was more isoniazid resistance among non-UK born 
cases than among UK-born cases (8.0%, 267/3,332 versus 
4.6%, 52/1,127) in 2013. The greatest number of cases of 
isoniazid-resistant TB occurred in people born in India, 
Pakistan and Somalia, while the greatest proportion of TB 
cases with isoniazid resistance occurred in those born in 
Ireland, Lithuania, Ukraine and Eritrea. There is an ongoing 
outbreak of isoniazid resistance in London (cluster E1244: 
strain type 424332431515321236423-52) which has affected 
mainly White and Black-Caribbean UK-born cases with 
social risk factors. Isoniazid resistance was more common 
in those with a previous history of TB among both UK-
born cases (5.3%, 4/75 versus 4.7%, 47/1,008) and non-UK 
born cases (10.7%, 18/169 versus 7.9%, 241/3,052). Social 
risk factors such as homelessness, imprisonment and 
misuse of drugs or alcohol were associated with isoniazid 
resistance, which occurred in 15.3% (28/183) of those 
reporting drug misuse and 15.4% (23/149) of those reporting 
imprisonment. 
 Of all notified cases of TB in 2013, 1.6% (74 cases) had MDR 
TB. The absolute number of cases of MDR TB has increased 
almost three-fold (86 cases in 2011; 82 cases in 2012) compared 
to figures a decade ago. In total, 87.3% of the UK MDR TB 
cases in 2013 arose in people born outside of the UK. While the 
highest absolute number of cases of MDR TB arose from India, 
Pakistan and Somalia, the highest proportion of cases arose 
from Ukraine, Lithuania, Latvia and Sierra Leone. MDR TB 
was more common in males than in females (1.7%, 48/2,764 
versus 1.4%, 26/1,842) and in the 15–44-year-old age group 
(2.1%, 61/2,931). A greater proportion of cases of MDR TB 
occurred in those with a previous history of TB than in those 
who had not previously had the disease (4.0%, 10/250 versus 
1.4%, 59/4,128). 
 Within the MDR TB population group, 17.4% (12/69) of 
those who were tested for resistance against the four first-
line drugs were resistant to all four of them. Half of MDR TB 
cases were resistant to at least one injectable agent. Those with 
resistance to an injectable agent were likely to be born in EU/
EEA countries (58.3%, 7/12) while those with resistance to a 
fluoroquinolone were likely to be born outside the EU/EEA 
(72.7%, 8/11). The proportion of MDR TB cases resistant to 
injectable agents rose from 2.1% in 2004 to 19.8% in 2012. This 
has been attributed at least in part to the rise in the number 
and proportion of such cases arising from Lithuania between 
2004 and 2013. Additionally, between 2010 and 2013, resistance 
to injectable agents was seen in all MDR TB cases from Russia 
as well as in at least half of MDR TB cases from China and 
Latvia. The majority of cases of MDR TB with fluoroquinolone 
resistance within this same time period arose among people 
born in India (45.5%, 20/44). 5 
 Management of MDR TB 
 Diagnosing drug resistance 
 Phenotypic drug susceptibility testing (DST) or rapid 
molecular diagnostics are required to make a diagnosis of 
drug-resistant TB. 6 Conventional methods of DST and culture 
take a significant amount of time to yield results regarding 
mycobacterial growth and drug resistance. This runs the risk 
of patients being treated with incorrect drugs in the interim, 
thus permitting further spread of drug-resistant strains and 
promoting the selection of strains with even greater resistance 
(ie extensively drug-resistant TB). Rapid diagnosis may 
improve prognosis and prevent further resistance emerging 
and spreading. The higher rates of drug-resistant TB in 
particular subpopulations in the UK, such as those from hard 
to reach groups and migrants from specific countries, means 
that clinicians should order rapid tests when a diagnosis of 
TB is suspected in individuals from these populations. The 
results of DST to different drugs can vary in accuracy and 
reproducibility. DST to rifampicin, isoniazid, fluoroquinolones 
and second-line injectable drugs are sufficiently accurate and 
reproducible, such that the results of their DSTs can be used to 
tailor individualised treatment regimens. Similarly reasonably 
reliable molecular tests for rifampicin and isoniazid resistance 
endorsed by the WHO are commercially available. 
 Treatment of MDR TB 
 Treating MDR TB can be complex and expensive due to the 
number of antibiotics required, the potential for serious 
adverse effects and the possibility of interactions with other 
medications. WHO guidance states that there are various 
general principles to consider when treating MDR TB. The 
full details of these principles can be found in the 2014 WHO 
publication  Companion handbook to the WHO guidelines for 
the programmatic management of drug-resistant tuberculosis . 6 
In brief, these are: use at least four effective antibiotics in the 
intensive phase which should last eight months (including 
pyrazinamide and an injectable); avoid toxic agents; use more 
antibiotics in more drug-resistant cases; use ambulatory care 
and administer the drugs with directly observed therapy; and 
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co-administer treatment with anti-retroviral drugs in patients 
who have HIV co-infection. The specific regimen for a patient 
will depend on their clinical history, DST results and contact 
history. The groups of drugs approved by WHO for treating TB 
are listed in Table 1. 6 
 The WHO advises caution against creating individualised 
regimens for patients based on DSTs to pyrazinamide, 
ethambutol, streptomycin, group-4 drugs and group-5 drugs, 
owing to problems with accuracy and reproducibility. The 
increasing occurrence of fluoroquinolone and injectable 
anti-TB drug resistance among MDR TB cases in the UK and 
the countries of origin of these patients should be taken into 
account when planning treatment regimens. 
 Duration of treatment 
 The intensive phase of MDR TB treatment refers to the length 
of time that patients receive injectable anti-TB drugs. WHO 
recommends that most MDR TB patients should receive the 
intensive phase of treatment for eight months. 6 Response 
to treatment is suggested by smear conversion and culture 
conversion. Other factors suggesting successful response to 
treatment include improvement or resolution of symptoms 
and pulmonary lesions on radiography. For those patients 
that do not undergo conversion by the eighth month, failure 
of treatment needs to be considered. The total duration of 
treatment depends on whether the patient has previously been 
treated for MDR TB. For those patients who have been newly 
diagnosed, treatment for a total of 20 months is recommended. 
This may be modified according to the individual patient's 
response to therapy. In those who have previously been treated 
with the MDR TB regimen, treatment for a minimum of 24 
months is recommended. 
 Extrapulmonary MDR TB 
 Most cases of extrapulmonary MDR TB can be treated in the 
same way as pulmonary MDR TB. 6 However in central nervous 
system (CNS) MDR TB, the ability of drugs to penetrate 
the CNS needs to be taken into consideration. Isoniazid, 
pyrazinamide, prothionamide/ethionamide and cycloserine are 
able to penetrate the CNS well, while several other drugs have 
poor penetration, variable penetration or data on their use in 
CNS MDR TB are currently lacking. 
 Surgical intervention in MDR TB 
 Surgical resection of all or part of the lung has been shown 
to be safe and effective and thus may be considered as an 
adjunct to drug therapy. 7 A minimum of two months of drug 
therapy should be administered prior to surgery. Surgery is not 
indicated if extensive bilateral disease is present. Surgery should 
take place when the patient's risk of morbidity or mortality is 
low: for example, when the disease is confined to a single lung. 6 
 Nutritional support 
 Nutritional support should be provided to all MDR TB patients, 
as malnutrition causes worsening of and is worsened by MDR 
TB. 8 This includes administering vitamin B6 (pyridoxine) in 
all MDR TB patients who are receiving isoniazid, linezolid, 
cycloserine or terizidone. 
 Adverse effects of MDR TB therapies 
 Recently, a guideline which succinctly describes the doses, 
adverse effects, interactions and monitoring requirements for 
each of the different drugs used in MDR TB has been published 
in the UK, providing a practical source of information for 
clinicians managing patients with the condition.  9,10 Adverse 
effects range from common reactions, such as nausea, vomiting, 
diarrhoea and arthralgia, to a range of more severe reactions. 
Management of adverse effects depends on the severity of the 
side effect and which drug is responsible. Drugs used in the 
treatment of MDR TB also exhibit a range of drug interactions 
that further add to the complexity of managing the disease 
(see below). Patients with MDR TB should be managed by 
physicians with expertise in MDR TB treatment. 
 Anti-retroviral therapy in MDR TB 
 Use of anti-retroviral therapy (ART) improves outcomes for 
patients who are co-infected with HIV and MDR TB. 11 WHO 
guidance states that ART is recommended for all patients 
with HIV and drug-resistant TB requiring second-line anti-
TB drugs, irrespective of CD4 cell-count, as early as possible 
(within the first eight weeks) following initiation of anti-TB 
treatment. 12 Of clinical concern is the possibility of adverse 
effects arising from the overlapping toxicities of anti-TB drugs 
and ART. 
 Table 1.  List of WHO-approved drugs for treating TB . 6 
Group Drugs 
1: First-line oral agents Isoniazid, rifampicin, ethambutol, pyrazinamide, rifabutin, rifapentine
2: Injectable anti-TB drugs Streptomycin, kanamycin, amikacin, capreomycin
3: Fluoroquinolones Levofloxacin, moxifloxacin, gatifloxacin
4: Oral bacteriostatic second-line anti-TB drugs Ethionamide, prothionamide, cycloserine, terizidone para-aminosalicylic acid, 
para-aminosalicylate sodium
5:  Anti-TB drugs with limited data on efficacy and/or 
long-term safety in the treatment of drug-resistant TB
Bedaquiline, delamanid, linezolid, clofazimine, amoxicillin/clavulanate, 
imipenem/cilastatin, meropenem, high-dose isoniazid, thioacetazone, 
clarithromycin
 TB = tuberculosis; WHO = World Health Organization. 
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 Drug–drug interactions may occur between second-line 
anti-TB drugs and ART agents. An online tool summarising 
all known interactions is available. 13 The interaction between 
fluoroquinolones and didanosine may cause decreased 
fluroquinolone absorption. Clarithromycin has several 
interactions with protease inhibitors and non-nucleoside 
reverse transcriptase inhibitors. 
 Technological advances in the management of 
MDR TB 
 The labour-intensive and slow nature of conventional 
diagnostic tests to identify drug resistance in TB increases 
the risk of inappropriate TB drugs being prescribed and thus 
increases the likelihood of further drug resistance arising. 
Improving the efficacy and reliability of diagnostic tests will be 
fundamental to successfully identify, treat and thus reduce the 
global spread of MDR TB. Similarly, new treatment regimens 
with a shorter duration of administration and drugs that are 
less toxic will improve patient outcomes. Several technologies 
have been created to begin to address this problem. 
 GeneXpert ® 
 The Xpert® MTB/RIF assay is an automated, real-time nucleic 
acid amplification assay that enables both the rapid detection of 
 M tuberculosis and the detection of mutations that may confer 
the bacterium with resistance to rifampicin. 14 Sputum is added 
to a treatment reagent which liquefies and inactivates bacteria. 
The liquefied sputum is transferred to a cartridge which is 
loaded into the device for the assay which is based on real-time 
PCR amplification of the  rpoB gene target. A systematic review 
examining the diagnostic accuracy of molecular genetic tests 
for TB drug resistance has shown that GeneXpert® is sensitive, 
specific and cost-effective. 15 It has been shown that a single, 
direct Xpert® MTB/RIF test detects 92.2% of culture positive 
patients, 16 with the proportion detected increasing as the 
number of specimens that are tested increases. Similarly, the 
addition of second and third Xpert® MTB/RIF tests in smear-
negative culture-positive patients increases the sensitivity of the 
test from 72.5 to 85.1 to 90.2% respectively. 16 The test has been 
shown to have a sensitivity of 99.1% in detecting rifampicin 
resistance and specificity of 100% in patients with rifampicin 
susceptibility, while its rate of indeterminate results (3.7%) was 
lower than the rate of culture contamination. 16 
 In settings with low MDR TBR prevalence and where risk 
of MDR TB is low, there is not yet agreement about whether 
rifampicin resistance should be confirmed using a second 
specimen before treatment for MDR TB is initiated. 17 It has 
further been suggested that the test's lower sensitivity in the 
context of less extensive disease may limit the utility of the 
test in low-incidence settings. 18 Furthermore, the test has been 
shown to give false negative results in the presence of particular 
 rpoB mutations that are associated with low-level rifampicin 
resistance. 19 
 Line probe assays 
 Line probe assays involve PCR amplification of  M tuberculosis 
DNA followed by hybridisation of labelled PCR products with 
specific oligonucleotide probes which are visualised as coloured 
bands on a strip. The process enables detection of  M tuberculosis 
and the presence of mutations that may confer resistance to 
drugs such as rifampicin. Mutations may be detected because 
the applied probes do not bind to the amplicon containing 
the mutation or they can be detected by using probes that 
are specific to a particular mutation. Line probe assays have 
been shown to have high sensitivity ( > 97%) and specificity 
( > 99%) for detecting rifampicin resistance in isolates from 
smear-positive sputum samples. Culture is still required for 
smear-negative specimens and DST is still required to confirm 
XDR TB; hence line probe assays are not currently considered 
a replacement for culture and DST. 20 Benefits of this technique 
include the rapid speed with which rifampicin resistance can 
be detected, normally within 48 hours. 21 Although the test has 
high sensitivity and specificity when used on culture isolates, it 
has lower sensitivity when used directly on clinical specimens. 22 
Additionally, it has been suggested that the reliability of the test 
in acting as a surrogate marker for MDR TB will depend on the 
prevalence of rifampicin resistance in the population. 23 
 Next-generation sequencing 
 Next-generation sequencing (NGS) refers to technologies 
capable of very rapid high-throughput DNA sequencing, 
whereby millions of sequences are read in parallel. This offers 
huge potential to establish disease susceptibility and facilitate 
the development of targeted therapies. 24 Studies have already 
illustrated a role for such technology in identifying drug 
resistance mutations in TB. 25,26 NGS enables sequencing of 
entire coding regions and allows polymorphisms involved in 
drug resistance in TB to be further characterised. However, the 
discordance between phenotypic tests and NGS indicates that 
some mutations may not have an impact on drug susceptibility, 
so it is important to correlate new mutations with clinical 
response to drugs before determining what the effect of a 
particular mutation may be. 25 
 New drugs and regimens 
 It was has been more than 40 years since the last new anti-TB 
drug, rifampicin, was introduced. 27 Since then, the increasing 
incidence of MDR TB has led to a significant drive to develop 
new drugs that can tackle the growing threat of multidrug 
resistance. Two such drugs which have been licensed recently 
for MDR TB are bedaquiline and delamanid. 
 Bedaquiline (TMC207), a diarylquinoline, functions by 
inhibiting mycobacterial ATP synthase 28 and has been developed 
to specifically treat MDR TB. It has been shown to be beneficial 
in phase-IIb trials 29 but data from phase-III trials are currently 
awaited. Nevertheless, the US Food and Drug Administration 
granted bedaquiline accelerated approval in December 2012 30 
and subsequently the WHO issued interim guidance on the 
appropriate use of the drug in the treatment of MDR TB. 31 
 Delamanid (OPC-67683) is a new nitro-hydro-imidazooxazole 
derivative that inhibits mycolic acid synthesis 32 with encouraging 
trial results so far. 33,34 It is currently under investigation in 
phase-III clinical trials as an adjunct to optimised background 
regimens for treating MDR TB, while other trials are currently 
evaluating the use of delamanid in children with MDR TB. In 
2013, the European Medicine Agency recommended delamanid 
as a treatment option for TB. 35 
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 A summary of phase III trials into new treatment regimens for 
MDR TB is provided in Table 2. 36 
 Beyond MDR TB: the threat of XDR TB 
 Treatment options are already severely limited for MDR TB. 
Affirmative action is therefore needed to halt the spread of drug 
resistance to avoid further spread of XDR TB which will be even 
more challenging to manage. 
 Cases of XDR TB were reported by 100 countries in 2013. 
Based on their combined data, an average of 9.0% (95% CI 
6.5–11.5%) of MDR TB cases had XDR TB. The countries 
reporting the highest proportions of MDR TB cases with XDR 
TB were Lithuania (24.8%), Kazakhstan (22.7%) and Latvia 
(21.7%). From the 1,269 patients in the global cohort of XDR 
TB patients in 2011: 22% completed treatment; 35% died; 
10% failed treatment; and 33% were lost to follow-up or the 
treatment outcome was not evaluated. 4 Data on treating XDR 
TB are limited. However it has been shown that a successful 
treatment outcome is more likely if at least six drugs are used in 
the intensive phase of treatment and four drugs are used in the 
continuation phase, and that outcomes are improved if later-
generation fluoroquinolones are used. 37,38 
 Future priorities 
 The WHO has set out five priorities to eliminate TB: (i) 
reaching the ‘missed’ cases; (ii) addressing MDR TB as a crisis; 
(iii) accelerating the response to TB/HIV; (iv) increasing 
financing to close resource gaps; and (v) intensifying research 
and ensuring uptake of innovations. 
 Given the limited treatments available for MDR TB and 
the increasing threat of XDR TB, it is essential to address 
deficits in current practice. A critical step will be treating TB 
at its source and decreasing its transmission by ensuring that 
patients with active disease are rapidly identified, investigated 
and treated with the correct medications to which the strain of 
 M tuberculosis causing their disease is sensitive. Additionally 
it will be important to improve patient adherence to anti-TB 
medications and to take steps to decrease the likelihood of 
patients being lost to follow up. This should include ensuring 
that patients with TB have access to free medications and 
free laboratory testing. This will require significant financial 
investment into local healthcare systems. Wealthier countries 
will need to support resource-limited nations so that the 
appropriate infrastructure can be put in place to meet this 
need, which includes facilitating the use of new technologies 
that have been developed for rapid diagnosis of drug resistance 
in TB. Furthermore, new drugs that are currently in the 
pipeline need to be not only efficacious but also cost effective, 
so that the financial implications of treating TB do not create 
a barrier for developing countries. There needs to be increased 
provision for palliative care services in the context of MDR 
TB and XDR TB. Provision of integrated care services will 
be imperative in curbing the spread of the disease and above 
all the wider social determinants of TB need to be addressed. 
Most importantly, visionary leadership is needed if we are to 
tackle the global threat of MDR TB. 39 ■ 
 Note 
 This article was originally published in the 2015 Clinical Medicine 
supplement Horizons in Medicine 27. All articles in this supplement 
are available at www.clinmed.rcpjournal.org/content/15/Suppl_6 
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